ClearPoint Neuro (CLPT) CFO awarded 66,273 restricted stock units

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

D'Alessandro Danilo reported acquisition or exercise transactions in this Form 4 filing.

ClearPoint Neuro, Inc. reported that Chief Financial Officer Danilo D'Alessandro received a grant of 66,273 restricted stock units. Each unit represents a contingent right to one share of CLPT common stock. The units vest 20% on February 17, 2027, 40% on February 17, 2028, and 40% on February 17, 2029.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider D'Alessandro Danilo

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	66,273	$0.00	--

Holdings After Transaction: Restricted Stock Units — 66,273 shares (Direct)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. The restricted stock units vest as follows: (i) 20% of the total shares on February 17, 2027; (ii) 40% of the total shares on February 17, 2028; and (iii) 40% of the total shares on February 17, 2029.

Form 4 Insider Transactions: What Each Field Means →

02/19/2026 - 04:09 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

D'Alessandro Danilo

(Last)

(First)

(Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH

92075

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	02/17/2026		A		66,273		⁽²⁾	⁽²⁾	Common Stock	66,273	$0	66,273	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of CLPT common stock.

2. The restricted stock units vest as follows: (i) 20% of the total shares on February 17, 2027; (ii) 40% of the total shares on February 17, 2028; and (iii) 40% of the total shares on February 17, 2029.

	/s/ Danilo D'Alessandro	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ClearPoint Neuro (CLPT) report for its CFO?

ClearPoint Neuro reported that its Chief Financial Officer, Danilo D'Alessandro, received a grant of 66,273 restricted stock units. These are equity awards, not open-market purchases, and each unit represents the right to receive one share of CLPT common stock upon vesting.

How many restricted stock units were granted to the ClearPoint Neuro (CLPT) CFO?

The CFO of ClearPoint Neuro was granted 66,273 restricted stock units. This entire amount was reported as acquired in a single Form 4 transaction, with zero dollar price per unit because it is a stock-based compensation award rather than a cash purchase.

What is the vesting schedule for the 66,273 RSUs at ClearPoint Neuro (CLPT)?

The 66,273 restricted stock units vest in three tranches: 20% on February 17, 2027, 40% on February 17, 2028, and 40% on February 17, 2029. This creates a multi-year incentive period for the Chief Financial Officer tied to continued service.

What does each restricted stock unit represent in the ClearPoint Neuro (CLPT) Form 4?

Each restricted stock unit reported in the Form 4 represents a contingent right to receive one share of ClearPoint Neuro common stock. The units convert into shares only as they vest on specified future dates, according to the disclosed vesting schedule.

Was the ClearPoint Neuro (CLPT) CFO’s RSU transaction a stock purchase or a grant?

The transaction was a grant of restricted stock units, not an open-market stock purchase. The Form 4 uses transaction code “A” for grant, and the reported price per unit is $0.0000, reflecting that it is compensation-based rather than a cash investment.

How many CLPT restricted stock units does the CFO hold after this grant?

After the reported grant, the ClearPoint Neuro Chief Financial Officer holds a total of 66,273 restricted stock units directly. This figure reflects the post-transaction balance of derivative securities as disclosed in the Form 4 filing data.